ASPIRIN HYPERSENSITIVITY IN CORONARY ARTERY DISEASE: PRACTICAL CHALLENGES AND MANAGEMENT APPROACHES

Doan Nu Ngoc Linh 1 , , Nguyen Van Tan 1, 2
1 University of Medicine and Pharmacy at Ho Chi Minh City image/svg+xml
2 Thong Nhat Hospital image/svg+xml
* Corresponding author:

Article Information

Metrics
Downloads: 71 Views: 87
DOI
10.63947/bvtn.v1i5.4
Published
2025-11-01
Issue Vol. 1 No. 5 (2025): Thong Nhat Hospital’s 50-Year Journey - Comprehensive Healthcare and Healthy Aging
Section
Review Article
Categories
Research

Download Article

PDF

How to Cite

1.
Nu Ngoc Linh D, Van Tan N. ASPIRIN HYPERSENSITIVITY IN CORONARY ARTERY DISEASE: PRACTICAL CHALLENGES AND MANAGEMENT APPROACHES. JHA [Internet]. Vietnam; 2025 Nov. 1 [cited 2025 Nov. 5];1(5):24–34. https://tcsuckhoelaohoa.vn/bvtn/article/view/93 doi: 10.63947/bvtn.v1i5.4
Loading citation...
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Aspirin is a cornerstone therapy for coronary artery disease (CAD), yet hypersensitivity complicates its use in clinical practice. This narrative review synthesizes contemporary evidence from studies and guidelines to provide pragmatic, evidence–based recommendations on the epidemiology, mechanisms, classification, and management of aspirin hypersensitivity. Prevalence is estimated at 0.5–1.9% in the general population and 2.6% among patients undergoing coronary angiography. In the ADAPTED (Aspirin Desensitization in Patients with Coronary Artery Disease) registry, a rapid desensitization protocol achieved a 95.4% success rate, with 80.3% of patients remaining on aspirin at 12 months. The 2025 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend aspirin desensitization as the preferred strategy in acute coronary syndromes (ACS). In contrast, the 2024 European Society of Cardiology (ESC) guidelines recommend clopidogrel for chronic coronary syndromes (CCS) when aspirin is not tolerated. Desensitization is contraindicated in patients with a history of severe anaphylaxis. Accordingly, desensitization should be preferred whenever feasible. When it is not possible or unsuccessful, alternatives—such as cilostazol, indobufen, or P2Y12 inhibitor–based regimens with or without oral anticoagulants—may be considered based on ischemic and bleeding risk. Robust randomized controlled trials are needed to confirm the efficacy of these strategies.

Keywords

aspirin hypersensitivity aspirin desensitization coronary artery disease

References

  1. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237.
  2. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537.
  3. Thong BY. Nonsteroidal anti-inflammatory drug hypersensitivity in the Asia-Pacific. Asia Pac Allergy. 2018;8(4):e38.
  4. McMullan KL. Aspirin allergy in patients with myocardial infarction: the allergist’s role. Ann Allergy Asthma Immunol. 2014;112(2):90-3.
  5. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation. 2016;134(20):1579-1594.
  6. Dona I, Perez-Sanchez N, Eguiluz-Gracia I, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(3):561-575.
  7. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti inflammatory drugs. Allergy. 2013;68(10):1219-32.
  8. Galli M, Occhipinti G, Angiolillo DJ. Aspirin hypersensitivity and intolerance. Eur Heart J Cardiovasc Pharmacother. 2024;10(3):173-174.
  9. Makowska J, Makowski M, Kowalski ML. NSAIDs Hypersensitivity: When and How to Desensitize? Current Treatment Options in Allergy. 2015;2(2):124-140.
  10. Cappannoli L, Colantuono S, Animati FM, et al. Aspirin Hypersensitivity in Patients with Coronary Artery Disease: An Updated Review and Practical Recommendations. Biomolecules. 2024;14(10).
  11. Rossini R, Iorio A, Pozzi R, et al. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circ Cardiovasc Interv. 2017;10(2).
  12. Manzo-Silberman S, Nicaise-Roland P, Neukirch C, et al. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. Eur Heart J Cardiovasc Pharmacother. 2017;3(2):77-81.
  13. Bianco M, Rossini R, Cerrato E, et al. Aspirin desensitization procedures in aspirin intolerant patients: a neglected topic in the ESC 2019 Chronic Coronary Syndrome guidelines. Eur Heart J. 2020;41(3):482.
  14. Xue Y, Feng ZW, Li XY, et al. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. Acta Pharmacol Sin. 2018;39(2):205-212.
  15. Wang MT, Liang HL, Hung CC, et al. Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study. CNS Drugs. 2019;33(2):175-185.
  16. Cavalcante DVS, Krishna MM, Joseph M, et al. Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta analysis. Vascul Pharmacol. 2025;158:107465.
  17. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799-1808.

License

© 2025 The Author(s). Published by Journal of Health and Aging.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.